By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Hemispherx Biopharma Inc. 

One Penn Center
1617 JFK Boulevard
Philadelphia  Pennsylvania  19103  U.S.A.
Phone: 215-988-0080 Fax: 215-988-1739


Company News
Hemispherx Biopharma (HEB) Awarded $770,852 by Federal Judge 1/15/2015 7:09:42 AM
Hemispherx Biopharma (HEB) Release: Low Natural Killer (NK) Activity Observed Across The Chronic Fatigue Syndrome (CFS) Disease Spectrum 1/12/2015 7:07:11 AM
Arrowhead Issues Diligence And Valuation Report On Hemispherx Biopharma (HEB) 1/9/2015 7:45:35 AM
Hemispherx Biopharma (HEB)'s Ampligen® Provides Anti-Tumor Activity Analogous To Emerging Immune Checkpoint Inhibitors 12/16/2014 8:07:45 AM
Hemispherx Biopharma (HEB) Announces Data Showing Inhibition Of Ebola By Ampligen® Enlarged By Howard University Research 12/9/2014 10:47:49 AM
Hemispherx Biopharma (HEB) Reports on Annual Stockholder Meeting 11/17/2014 2:13:11 PM
Hemispherx Biopharma (HEB) Release: Ampligen(R) Blocks Critical Ebola Viral Disease (EVD) Protein Which Is Linked To High Mortality In Man 11/17/2014 12:28:03 PM
Hemispherx Biopharma (HEB) Announces Financial Results For The Nine Months Ended September 30, 2014 11/10/2014 7:49:06 AM
Hemispherx Biopharma (HEB) And United States Army Medical Research Institute Of Infectious Diseases (USAMRIID) Collaborate On Alferon® And Ampligen® Against The Ebola Virus 11/3/2014 7:26:09 AM
Hemispherx Biopharma (HEB) Reports New Evidence -- Based Potential Of Ampligen® Against Ebola Virus Disease (EVD) 10/30/2014 7:59:17 AM